EANS-News: SYGNIS Pharma AG / SYGNIS announces completion of the X-Pol Biotech acquisition

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital measures

Heidelberg (euro adhoc) - SYGNIS announces completion of the X-Pol
Biotech acquisition

· Registration of the transaction and the previous capital reduction
(ratio of 8:1) in the Commercial Register
· New share capital of the Company EUR 9,349,724
· New ISIN DE000A1RFM03
· New Ticker symbol LIO1

Heidelberg, December 6, 2012 - SYGNIS Pharma AG (Frankfurt: LIO1;
ISIN: DE000A1RFM03, Prime Standard) announced today that the merger
with X-Pol Biotech S.L. (X-Pol) is completed. With the approval of
the Annual General Meeting on October 17, 2012 SYGNIS acquired 100%
of the shares of the Spanish X-Pol by way of a capital increase
against contribution in kind. This transaction is completed with the
registration of the capital increase in the Commercial Register. Thus
X-Pol becomes a 100% subsidiary of SYGNIS and SYGNIS' share capital
is increased from EUR 2,103,688 to EUR 9,349,724. After this
transaction, the former shareholders of X-Pol hold 77.5% of SYGNIS
shares. The previous shareholders of SYGNIS now own 22.5% of the new
company. No shares were sold in the capital market.

Before the capital increase, a reduction of SYGNIS' share capital
from EUR 16,829,504 to EUR 2,103,688 by consolidation of shares in
the ratio of 8:1 was executed. Thereby, eight no par value bearer
shares with ISIN DE000A1E9B74 were merged into one converted no par
value bearer share with the new ISIN DE000A1RFM03. Accordingly, the
depositary banks have converted the individual deposits of SYGNIS
shares as they were on December 5, 2012.

If a shareholder did not hold a number of shares divisible by eight,
a fraction of shares, this means a partial entitlement to receive one
share (ISIN DE000A1RFM11), is booked for the shareholder. In order to
be converted into full rights (so-called peak regulation), a
corresponding buy or sell order is required. Each required peak
regulation will be executed by the respective custodian bank by close
of business December 21, 2012.

The first listing on December 6, 2012 will be based on the trading
price of the SYGNIS share as of December 5, 2012 and will be
correspondingly increased by a factor of eight.

For further information please contact:

Peter Willinger
CFO
SYGNIS Pharma AG

Tel.: +49 6221 454 836
E-mail: peter.willinger@sygnis.de

About SYGNIS Pharma AG: www.sygnis.de

SYGNIS Pharma AG (Heidelberg, Germany) is a specialized biotech
company listed in the Prime Standard of the German Stock Exchange
(Ticker: LIO1; ISIN: DE000A1RFM03). So far, the business focus was on
the research and development of innovative therapies for the
treatment of diseases of the central nervous system. After the AXIS 2
study showed no efficacy of AX200 for the treatment of acute stroke,
the program was discontinued. The company is currently continuing the
KIBRA project. With the acquisition of X-Pol, SYGNIS will realign.
The future focus of the company will be in the field of molecular
diagnostics.

About X-Pol Biotech, S.L.: www.xpolbiotech.com

X-Pol Biotech, S.L. (Madrid, Spain) is a biotechnology company
created by Prof. Luis Blanco and GENETRIX in 2008 with a focus on the
development of tools and technologies for the DNA amplification and
sequencing market. In July 2012 X-Pol has licensed its key product,
an improved polymerase for amplifying DNA called "Qualiphi®" to
Qiagen for its worldwide commercialisation.

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or
goals. These statements should not be considered to be total
guarantees since given their very nature they are subject to known
and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals
of SYGNIS Pharma AG may deviate greatly from the established
conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for
any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1RFM03
indexes:
stockmarkets:
language: English